← FDA DRUG APPROVALS

FDA ANDA · ANDA207645

GANCICLOVIR

ganciclovir sodium

Sponsor: PHARMASCIENCE INC

APPLICATION
ANDA207645
TYPE
ANDA
ORIGINAL APPROVAL
2017-12-08
LATEST ACTION
2024-02-15
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

GANCICLOVIR SODIUMPrescription
GANCICLOVIR SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-02-15Labeling · Supplement 2 · standardAP
2020-05-18Labeling · Supplement 1 · standardAP
2017-12-08UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →